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Abstract
Mass spectrometry (MS) analysis for detection of immunoglobulins (IG) of the human IgG3 subclass is described that relies
on polymorphic amino acids of the heavy gamma3 chains. IgG3 is the most polymorphic human IgG subclass with thirteen
G3m allotypes located on the constant CH2 and CH3 domains of the gamma3 chain, the combination of which leads to six
major G3m alleles. Amino acid changes resulting of extensive sequencing previously led to the definition of 19 IGHG3 alleles
that have been correlated to the G3m alleles. As a proof of concept, MS proteotypic peptides were defined which
encompass discriminatory amino acids for the identification of the G3m and IGHG3 alleles. Plasma samples originating from
ten individuals either homozygous or heterozygous for different G3m alleles, and including one mother and her baby
(drawn sequentially from birth to 9 months of age), were analyzed. Total IgG3 were purified using affinity chromatography
and then digested by a combination of AspN and trypsin proteases, and peptides of interest were detected by mass
spectrometry. The sensitivity of the method was assessed by mixing variable amounts of two plasma samples bearing
distinct G3m allotypes. A label-free approach using the high-performance liquid chromatography (HPLC) retention time of
peptides and their MS mass analyzer peak intensity gave semi-quantitative information. Quantification was realized by
selected reaction monitoring (SRM) using synthetic peptides as internal standards. The possibility offered by this new
methodology to detect and quantify neo-synthesized IgG in newborns will improve knowledge on the first acquisition of
antibodies in infants and constitutes a promising diagnostic tool for vertically-transmitted diseases.
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Introduction
Systemic transfer of maternal antibodies occurs in utero across
the placenta. It is limited to the immunoglobulins (IG) of the IgG
class which are transported across the syncytiotrophoblasts via a
specific pathway involving the placental Fc receptor (FCGRT) [1].
This active transport mechanism of maternal IgG to the fetus
usually results in about 90% of the maternal serum level of IgG in
the full-term newborn at delivery [2]. Plasma IgG concentrations
are in the 7–15 g/L range and IgG account for 75% of serum IG
in a human adult. They are constituted of IgG1 (60–70%), IgG2
(20–30%), IgG3 (5–8%) and IgG4 (1–3%) [3]. The length of time
during which maternal antibodies persist in the infant’s blood
depends on the starting antibody concentration at birth. In
general, maternal antibodies fall to minimal levels by 4 months of
age and the infant’s antibody titres begin to rise from about 6
months of age, following active immunization. Presence in the
infant’s plasma of both maternal and intrinsic antibodies hampers
the neonatal serological diagnosis. If a direct diagnosis is
impossible or is insufficient, the detection of the neonate’s own
antibodies can bring essential information especially for vertically-
transmitted diseases for which the methods of antigen detection
are not reliable. It is the case of parasitic diseases such as
toxoplasmosis (causal agent: Toxoplasma gondii) and the American
trypanosomiasis also named Chagas disease (causal agent:
Trypanosoma cruzi), for which the determination of specific
antibodies neo-synthesized by the newborn would be helpful
during the first months of life to diagnose a congenital infection
[4–6]. The decision to establish or to shorten medical treatments
would be facilitated by the observation of specific antibodies
elaborated by the newborn. This requires being able to distinguish
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IG synthesized by the infant from those transferred from the
mother.
On the constant regions of their heavy gamma1, gamma2 and
gamma3 chains, the IgG1, IgG2 and IgG3 subclasses carry
antigenic determinants or Gm (for gamma marker) allotypes [7,8].
Twenty Gm allotypes are currently identified (18 ‘classical’ ones
and two ‘surnumerary’ ones). The 18 ‘classical’ Gm allotypes
comprise four G1m, G1m (1, 2, 3, 17), one G2m, G2m (23), and
thirteen G3m, G3m (5, 6, 10, 11, 13, 14, 15, 16, 21, 24, 26, 27, 28)
[8]. The two ‘surnumerary’ allotypes, G1m27 and G1m28,
correspond to allotypes demonstrated to be located in gamma1
chains in African populations, instead of being on gamma3, as
expected [8,9]. Except for G1m3 and G1m17 located on the CH1
domain of gamma1, all other Gm allotypes are located on the Fc
(on CH2 or on CH3) [8]. The correlation between Gm allotypes
and amino acid changes has been possible following the
sequencing of gamma chains and/or IGHG genes [10], and the
complete nucleotide sequencing of many IGHG3 alleles from
individuals homozygous for well characterized G3m alleles [8,10–
12]. The thirteen G3m allotypes are inherited in different
combinations or G3m alleles (encoded by one or several IGHG3
alleles) [8]. The six prevalent alleles are G3m5*
(G3m5,10,11,13,14,26,27), G3m6* (G3m5,6,10,11,14,26,27),
G3m24* (G3m5,6,11,24,26), G3m15* (G3m10,11,13,15,27),
G3m16* (G3m10,11,13,15,16,27) and G3m21*
(G3m21,26,27,28) [8]. Several G3m allotypes depend on the
combination of two or even three amino acids, distant on the
linear sequence but close to one another in three-dimensional
structures (illustrated in the ‘IMGT G3m allele butterfly’
representation) [8]. The G1m, G2m and G3m alleles themselves,
encoded by alleles of the closely linked IGHG genes, are inherited
in fixed combinations or Gm haplotypes [7,8].
The Gm polymorphism has been extensively studied in human
populations, showing that a limited number of haplotypes are
observed worldwide, with high frequency variations among
populations from different continents [8,13]. To date, the classical
way to determine Gm allotypes is a serological hemagglutination
inhibition method [14,15]. This qualitative method will be
abandoned in a near future, principally because of depletion in
the collections of monospecific anti-allotype sera, obtained in the
past from blood donors, and because of the difficulty of obtaining
well characterized reagent monoclonal antibodies [16]. This
approach is unfortunately not able to distinguish between
maternal and neonatal phenotypes. Molecular techniques imply-
ing either polymerase chain reaction (PCR)-restriction fragment
length polymorphism (RFLP) [17] or extensive gene sequencing
[12] allow discrimination between sequences coding for the
various allotypes. However these methods are not adapted to
our topic of detection and quantification of neonatal antibody
production.
As the sequences of the IGHG genes and alleles and their
correspondence with the Gm alleles are known [8], a proteomic
approach aimed at measuring peptides containing discriminatory
amino acids by mass spectrometry (MS) could therefore represent
a novel methodology to determine Gm3 and IGHG3 alleles and to
distinguish maternal and neonatal antibodies. The objectives were
i) to determine in silico the peptides that could discriminate
between G3m and IGHG3 alleles, ii) to purify the IgG fraction
with an enrichment in IgG3, iii) to detect and quantify the
discriminatory peptides by mass spectrometry and iv) to test the
sensitivity of our approach.
This study is a proof-of-concept step towards using mass
spectrometry to detect G3m and IGHG3 alleles and to quantify
them, and to distinguish maternal and infant IgG3 in neonate
plasma samples where both are physiologically present.
Methods
Definition of Proteotypic Peptides Specific for the Human
G3m and IGHG3 Alleles
Proteotypic peptides were defined by comparing the amino acid
sequences of the constant regions of the four IgG subclass heavy
chains gamma1, gamma2, gamma3 and gamma4, encoded by the
Homo sapiens IGHG1, IGHG2, IGHG3 and IGHG4 genes,
respectively [3,18] [IMGT Repertoire (Sections: Protein display,
Allotypes) at IMGTH, the international ImMunoGeneTics infor-
mation systemH [19] (http://www.imgt.org). Sequences were
virtually cleaved by AspN and trypsin proteases allowing potential
miscleavage. All peptides were compared to determine those that
were specific to IGHG3 and discriminatory for G3m and IGHG3
alleles [8,10,12,20]. A list was defined, which comprised 32
proteotypic peptides suitable for IGHG3 polymorphism analysis
using liquid chromatography (LC) matrix-assisted laser desorp-
tion/ionization (MALDI) or electrospray ionisation (ESI) tandem
mass spectrometry (MS/MS) (Table 1).
These peptides are discriminatory for the G3m alleles and the
IGHG3 alleles [8] (Table 2). Twenty-three peptides are discrim-
inatory for one single G3m allele. Nine of these peptides are even
discriminatory for a single IGHG3 allele: peptide (#6, G3m5*) for
the IGHG3*09 allele, peptides (#11, #16, #21, #26, #30,
G3m24*) for the IGHG3*03 allele, and peptides (#22, #27, #31,
Gm6*) for the IGHG3*13 allele. Two pairs of peptides have
identical sequences (#19 and #20, and #24 and #25,
respectively), each member of the pair corresponding to different
G3m alleles, G3m5* (#19 and#24) and G3m21* (#20 and#25).
In those cases, the detection of another peptide should be required
for an unambiguous G3m assignment, e.g., #15 for G3m5* or
#17 for G3m21*, in the absence of serological data. The G3m
alloypes, in contrast to nonimmunogenic amino acid polymor-
phisms, may depend on two or even three amino acids [8] found,
after enzymatic digestion, on different peptides (Table 2).
Given the data complexity but also the richness of
information (detailed in [8]), some peptides detected in this
work are briefly presented. The peptide DIAVEWESSGQPEN-
NYNTTPPML (#15, Gm5*) is unambiguously discriminatory
for the G3m5* (G3m5,10,11,13,14,26,27) allele, as it contains
the amino acid characteristic for the G3m11 allotype: IGHG3
CH3 S44 (in bold in the peptide). In contrast, as mentioned
above, to be discriminatory for the G3m5* allele, the peptides
SRWQQGNIFSCSVMHEALHNR (#19) and WQQGNIFS
CSVMHEALHNR (#24) need to be detected with #15.
Indeed they contain the amino acids characteristic for the
G3m10,13,26,27 allotypes: IGHG3 CH3 Q98 (in bold) which,
associated to S44 in the complete protein (and present in #15
and required), corresponds to G3m13, IGHG3 CH3 R115 (in
bold) which corresponds to G3m26, and IGHG3 CH3 I101 (in
bold) which corresponds to G3m27 and, associated to S44 (see
above #15), to G3m10 [8] (positions are according to IMGT
unique numbering for C domain [21]) (Table 2). In contrast,
the peptide WQEGNVFSCSVMHEALHNR (#26) is highly
discriminatory for the G3m24* (G3m5,6,11,24,26) allele, as it
has a unique sequence and contains the amino acids
characteristic for the G3m6,24 allotypes: IGHG3 CH3 E98
(in bold) which, associated to S44 in the complete protein (and
present in #16, but detection was not compulsory), corresponds
to G3m6; and IGHG3 CH3 V101 (in bold) which, associated to
S44 (see above #16), corresponds to G3m24 [8]. Similarly, the
MS/MS Detection of G3m, IGHG3 Alleles and IgG3
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peptide WQEGNIFSCSVMHEALHNR (#27) is highly dis-
criminatory for the G3m6* (G3m5,6,10,11,14,26,27) allele, as it
contains the amino acids characteristic of the G3m6,27
allotypes: IGHG3 CH3 E98 (in bold) which, associated to
S44 in the complete protein (and present in #13, but detection
was not compulsory), corresponds to G3m6; and IGHG3 CH3
I101 (in bold) which corresponds to G3m27 and, associated to
S44 (see above #13), to G3m10 [8].
Table 2 shows that among the 9 peptides that are discriminatory
for more than one G3m allele, 5 peptides (#9, #14, #18, #23
and #28) correspond to 2 G3m alleles and 3 IGHG3 alleles
[Gm15* (IGHG3*17), and Gm16* (IGHG3*18 and *19)], 2
peptides (#8, #13) correspond to 2 G3m alleles and 3 IGHG3
alleles [G3m5* (IGHG3*06 and *07) and G3m6* (IGHG3*13)]
whereas only 2 peptides are not discriminatory, being found in 4
(#2) and 5 (#5) different G3m alleles.
Plasma Samples Collection
Plasma samples from ten individuals were analyzed. One blood
sample was collected in France from a healthy adult volunteer
(EUA1: EUropean Adult 1) who gave her written informed
consent for her blood to be used for the purpose of the present
study. Plasma samples from nine African individuals were
obtained from two studies performed on human genetic determi-
nants of malaria in the south of Benin by the UMR 216 team, and
for which ethical clearance was obtained. Four of these samples
originated from a study conducted in 2006–2007 among 155
schoolchildren (BEC1 to BEC4: BEninese Children 1 to 4)
Table 1. Mass-to-charge ratios (m/z) of thirty-two G3m and IGHG3 allele peptides after AspN and trypsin digestion.
Theoretical proteotypic peptides Miscleavage m/z charge state
+1 +2 +3 +4
#1 K. TKPWEEQYNSTFR. V 0 1685.79 843.40 562.60
#2 K. TKPREEQYNSTFR. V 1 1655.81 828.41 552.60 414.70
#3 K. LREEQYNSTFR. V 1 1442.70 721.85 481.57
#4 V. DGVEVHNAKTKPWEEQYNSTFR. V 1 2635.25 1318.13 879.08 659.56
#5 R. EEQYNSTFRVVSVLTVLHQ. D 1 2249.15 1125.08 750.38 563.04
#6 R. EEQYNSTFRVVSVLTVVHQ. D 1 2235.14 1118.07 745.71 559.54
#7 K. TKPWEEQYNSTFRVVSVLTVLHQ. D 1 2761.43 1381.22 921.14 691.11
#8 K. GFYPSDIAVEWESSGQPENNYK. T 1 2517.12 1259.06 839.71 630.03
#9 K. GFYPSDIAMEWESSGQPENNYK. T 1 2549.09 1275.05 850.36 638.02
#10 K. GFYPSDIAVEWESSGQPENNYNTTPPML. D 1 3143.39 1572.20 1048.46 786.60
#11 K. GFYPSDIAVEWESSGQPENNYNTTPPVL. D 1 3128.39 1564.70 1043.46 782.85
#12 K. GFYPSDIAVEWESNGQPENNYNTTPPML. D 1 3111.42 1556.21 1037.81 778.61
#13 S. DIAVEWESSGQPENNYK. T 0 3170.40 1585.70 1057.47 793.35
#14 S. DIAMEWESSGQPENNYK. T 0 1965.88 983.44 655.96 492.22
#15 S. DIAVEWESSGQPENNYNTTPPML. D 0 1997.85 999.43 666.62 500.21
#16 S. DIAVEWESSGQPENNYNTTPPVL. D 0 2592.16 1296.58 864.72 648.79
#17 S. DIAVEWESNGQPENNYNTTPPML. D 0 2577.16 1289.08 859.72 645.04
#18 K. SRWQQGNIFSCcSVMHEALHNHYTQK. S 1 2560.18 1280.59 854.06 640.80
#19 K. SRWQQGNIFSCcSVMHEALHNR. F 1 2619.17 1310.09 873.72 655.54
#20 K. SRWQQGNIFSCcSVMHEALHNR. Y 1 3058.42 1529.71 1020.14 765.36
#21 K. SRWQEGNVFSCcSVMHEALHNR. F 1 2557.19 1279.10 853.06 640.05
#22 K. SRWQEGNIFSCcSVMHEALHNR. F 1 2544.16 1272.58 848.72 636.79
#23 R. WQQGNIFSCcSVMHEALHNHYTQK. S 0 2558.18 1279.59 853.39 640.30
#24 R. WQQGNIFSCcSVMHEALHNR. F 0 2815.28 1408.14 939.09 704.57
#25 R. WQQGNIFSCcSVMHEALHNR. Y 0 2314.06 1157.53 772.02 579.27
#26 R. WQEGNVFSCcSVMHEALHNR. F 0 2301.03 1151.02 767.68 576.01
#27 R. WQEGNIFSCcSVMHEALHNR. F 0 2315.04 1158.02 772.35 579.51
#28 R. WQQGNIFSCcSVMHEALHNHYTQKSLSLSPGK 1 3584.72 1792.86 1195.57 896.93
#29 R. WQQGNIFSCcSVMHEALHNRFTQK. S 1 2818.33 1409.67 940.11 705.33
#30 R. WQEGNVFSCcSVMHEALHNRFTQK.S 1 2805.30 1403.15 935.77 702.08
#31 R. WQEGNIFSCcSVMHEALHNRFTQK. S 1 2819.31 1410.16 940.44 705.58
#32 R. WQQGNIFSCcSVMHEALHNRYTQK. S 1 2834.32 1417.66 945.44 709.33
The proteotypic peptides correspond to an enzymatic AspN and trypsin digestion of the constant region of the IG gamma3 chains encoded by the Homo sapiens IGHG3
gene. Masses are determined for detection on the MALDI TOF and ESI Orbitrap mass spectrometers. The methionine (M) could be oxidized (+16 Da). m/z : mass-to-
charge ratio; +1, +2, +3, +4 represent the peptide charge state; amino acids in bold are implicated in the discrimination between G3m and IGHG3 alleles (detailed in
Table 2); «.» : site of enzymatic cut; Cc : carbamidomethylated cysteine.
doi:10.1371/journal.pone.0046097.t001
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Table 2. Characteristics of the thirty-two proteotypic peptides for Homo sapiens G3m and IGHG3 alleles.
Theoretical proteotypic peptides
CH
domains
Positions in CH
domains [21]
Allotype and other
polymorphic amino
acids [8]
IGHG3
alleles from
IMGT/GENE-
DB [18] G3m alleles
Simplified
form [8]
Complete
description [8]
#1 K. TKPWEEQYNSTFR. V CH2 79–85 P82 (nG3m21),
W83 (G3m16), Y84.3
IGHG3*18, *19 G3m16* G3m10,11,13,
15,16,27
#2 K. TKPREEQYNSTFR. V CH2 79–85 P82 (nG3m21), R83,
Y84.3
IGHG3*01, *02a, *04,
*05, *06, *07, *09, *10
G3m5* G3m5,10,11,13,
14,26,27
IGHG3*03 G3m24* G3m5,6,11,24,26
IGHG3*08 Unusualb G3m5,14,26,27
IGHG3*13 G3m6* G3m5,6,10,11,
14,26,27
IGHG3*17 G3m15* G3m10,11,13,15,27
#3 K. LREEQYNSTFR. V CH2 81–85 L82 (G3m21), R83, Y84.3 IGHG3*14, *15, *16 G3m21* G3m21,26,27,28
#4 V. DGVEVHNAKTKPWEEQYNSTFR. V CH2 43–85 P82, (nG3m21),
W83 (G3m16), Y84.3
IGHG3*18, *19 G3m16* G3m10,11,13,
15,16,27
#5 R. EEQYNSTFRVVSVLTVLHQ. D CH2 83–95 R83, Y84.3, L92 IGHG3*01, *02a, *04,
*05, *06, *07, *10
G3m5* G3m5,10,11,13,
14,26,27
IGHG3*03 G3m24* G3m5,6,11,24,26
IGHG3*08 Unusualb G3m5,14,26,27
IGHG3*13 G3m6* G3m5,6,10,11,
14,26,27
IGHG3*17 G3m15* G3m10,11,13,15,27
IGHG3*14, *15, *16 G3m21* G3m21,26,27,28
#6 R. EEQYNSTFRVVSVLTVVHQ. D CH2 83–95 R83, Y84.3, V92 IGHG3*09 G3m5* G3m5,10,11,13,
14,26,27
#7 K. TKPWEEQYNSTFRVVSVLTVLHQ. D CH2 79–95 P82, W83 (G3m16),
Y84.3, L92
IGHG3*18, *19 G3m16* G3m10,11,13,
15,16,27
#8 K. GFYPSDIAVEWESSGQPENNYK. T CH3 26–80 V39, S44 (G3m11), K79 IGHG3*06, *07 G3m5* G3m5,10,11,13,
14,26,27
IGHG3*13 G3m6* G3m5,6,10,11,
14,26,27
#9 K. GFYPSDIAMEWESSGQPENNYK. T CH3 26–80 M39 (G3m15d),
S44 (G3m11), K79
IGHG3*17 G3m15* G3m10,11,13,15,27
IGHG3*18, *19 G3m16* G3m10,11,13,
15,16,27
#10 K. GFYPSDIAVEWESSGQPENNYNTTPPML. D CH3 26–84.2 V39, S44 (G3m11), N79,
M84
IGHG3*01, *04, *05,
*09, *10, *11c, *12c
G3m5* G3m5,10,11,13,
14,26,27
#11 K. GFYPSDIAVEWESSGQPENNYNTTPPVL. D CH3 26–84.2 V39, S44 (G3m11), N79,
V84
IGHG3*03 G3m24* G3m5,6,11,24,26
#12 K. GFYPSDIAVEWESNGQPENNYNTTPPML. D CH3 26–84.2 V39, N44 (nG3m11), N79,
M84
IGHG3*08 Unusualb G3m5,14,26,27
IGHG3*14, *16 G3m21* G3m21,26,27,28
#13 S. DIAVEWESSGQPENNYK. T CH3 33–80 V39, S44 (G3m11), K79 IGHG3*06, *07 G3m5* G3m5,10,11,13,
14,26,27
IGHG3*13 G3m6* G3m5,6,10,11,
14,26,27
#14 S. DIAMEWESSGQPENNYK. T CH3 33–80 M39 (G3m15d),
S44 (G3m11), K79
IGHG3*17 G3m15* G3m10,11,13,15,27
IGHG3*18, *19 G3m16* G3m10,11,13,
15,16,27
#15 S. DIAVEWESSGQPENNYNTTPPML. D CH3 33–84.2 V39, S44 (G3m11), N79,
M84
IGHG3*01, *04, *05,
*09, *10, *11c, *12c
G3m5* G3m5,10,11,13,
14,26,27
#16 S. DIAVEWESSGQPENNYNTTPPVL. D CH3 33–84.2 V39, S44 (G3m11), N79,
V84
IGHG3*03 G3m24* G3m5,6,11,24,26
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Table 2. Cont.
Theoretical proteotypic peptides
CH
domains
Positions in CH
domains [21]
Allotype and other
polymorphic amino
acids [8]
IGHG3
alleles from
IMGT/GENE-
DB [18] G3m alleles
#17 S. DIAVEWESNGQPENNYNTTPPML. D CH3 33–84.2 V39, N44 (nG3m11), N79,
M84
IGHG3*08 Unusualb G3m5,14,26,27
IGHG3*14, *16 G3m21* G3m21,26,27,28
#18 K. SRWQQGNIFSCSVMHEALHNHYTQK. S CH3 93–120 Q98 (G3m13e),
I101 (G3m27, G3m10f),
H115+ Y116
(nG3m5, G3m15g)
IGHG3*17 G3m15* G3m10,11,13,15,27
IGHG3*18, *19 G3m16* G3m10,11,13,
15,16,27
#19 K. SRWQQGNIFSCSVMHEALHNR. F CH3 93–116 Q98 (G3m13e), I101
(G3m27, G3m10f), R115
(G3m26) + F116 (G3m5,
G3m14h)
IGHG3*01, *04,
*05, *06, *07,
*09, *10, *11c, *12c
G3m5* G3m5,10,11,13,14,
26,27
IGHG3*08 Unusualb G3m5,14,26,27
#20 K. SRWQQGNIFSCSVMHEALHNR. Y CH3 93–116 Q98, I101 (G3m27),
R115 (G3m26) + Y116
(G3m28)
IGHG3*14, *15, *16 G3m21* G3m21,26,27,28
#21 K. SRWQEGNVFSCSVMHEALHNR. F CH3 93–116 E98 (G3m6i), V101
(G3m24j),
R115 (G3m26) +
F116 (G3m5)
IGHG3*03 G3m*24 G3m5,6,11,24,26
#22 K. SRWQEGNIFSCSVMHEALHNR. F CH3 93–116 E98 (G3m6i),
I101 (G3m27, G3m10f),
R115 (G3m26) + F116
(G3m5, G3m14h)
IGHG3*13 G3m6* G3m5,6,10,11,
14,26,27
#23 R. WQQGNIFSCSVMHEALHNHYTQK. S CH3 95–120 Q98 (G3m13e), I101
(G3m27, G3m10f),
H115+ Y116 (nG3m5,
G3m15g)
IGHG3*17 G3m15* G3m10,11,13,15,27
IGHG3*18, *19 G3m16* G3m10,11,13,15,
16,27
#24 R. WQQGNIFSCSVMHEALHNR. F CH3 95–116 Q98 (G3m13e), I101
(G3m27, G3m10f), R115
(G3m26) + F116 (G3m5,
G3m14h)
IGHG3*01, *04,
*05, *06, *07,
*09, *10, *11c, *12c
G3m5* G3m5,10,11,13,
14,26,27
IGHG3*08 Unusualb G3m5,14,26,27
#25 R. WQQGNIFSCSVMHEALHNR. Y CH3 95–116 Q98, I101 (G3m27),
R115 (G3m26) + Y116
(G3m28)
IGHG3*14, *15, *16 G3m21* G3m21,26,27,28
#26 R. WQEGNVFSCSVMHEALHNR. F CH3 95–116 E98 (G3m6i), V101
(G3m24j),
R115 (G3m26) +
F116 (G3m5)
IGHG3*03 G3m24* G3m5,6,11,24,26
#27 R. WQEGNIFSCSVMHEALHNR. F CH3 95–116 E98 (G3m6i),
I101 (G3m27, G3m10f),
R115 (G3m26) + F116
(G3m5, G3m14h)
IGHG3*13 G3m6* G3m5,6,10,11,14,
26,27
#28 R. WQQGNIFSCSVMHEALHNHYTQKSLSLSPGK CH3 95–130 Q98 (G3m13e), I101
(G3m27, G3m10f),
H115+ Y116 (nG3m5,
G3m15g)
IGHG3*17 G3m15* G3m10,11,13,15,27
IGHG3*18, *19 G3m16* G3m10,11,13,15,
16,27
#29 R. WQQGNIFSCSVMHEALHNRFTQK. S CH3 95–120 Q98 (G3m13e), I101
(G3m27, G3m10f),
R115 (G3m26) + F116
(G3m5, G3m14h)
IGHG3*01, *04,
*05, *06, *07,
*09, *10, *11c, *12c
G3m5* G3m5,10,11,13,14,
26,27
IGHG3*08 Unusualb G3m5,14,26,27
#30 R. WQEGNVFSCSVMHEALHNRFTQK.S CH3 95–120 E98 (G3m6i), V101
(G3m24j), R115
(G3m26) + F116 (G3m5)
IGHG3*03 G3m*24 G3m5,6,11,24,26
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belonging mainly to the Fon ethnic group [22]. Acceptance of the
study was first obtained near the coordinating doctor of the
sanitary zone and the inspector of education. Oral information on
the study was thereafter provided by the research team to the
school director and the teachers before being dispensed to the
members of the association of schoolchildren’s parents. A
collective written informed consent was obtained from the head/
person in charge of the association of parents, which took into
account their individual positions. The study was authorized by
the institutional ‘‘Ethics Committee of the Faculte´ des Sciences de
la Sante´’’ (FSS) from the Universite´ d’Abomey-Calavi (UAC) in
Benin. The five other plasma samples concerned a mother and
child pair (BEM1: BEninese Mother 1 and BEI1: BEninese Infant
1) as well as three other mothers (BEM2 to BEM4) issued from a
malaria birth cohort of 627 neonates and their mothers who were
followed-up from 2007 to 2010 in a semi-rural area [23]. At
delivery, maternal peripheral blood and infant cord blood were
drawn. Thereafter, the blood of child BEI1 was collected quarterly
until he reached eighteen months. Plasma samples at 3, 6 and 9
months of age were selected for the purpose of the study. Upon
arrival at the maternity clinic for delivery, women were given
information on the study protocol. The informed consent written
in French and in Fon was then submitted for approval. The
protocol was approved by both the institutional ‘‘Ethics Commit-
tee of the Faculte´ des Sciences de la Sante´’’ (FSS) in Benin and the
IRD ‘‘Consultative Committee on Professional Conduct and
Ethics’’ (CCDE) in France.
In all cases, blood was collected into 5 mL EDTA VacutainerH
tubes and after centrifugation, plasma samples were frozen at
220uC. One milliliter of fresh plasma from the European
individual was also analyzed by comparison with the frozen one.
Serological Determination of Gm Allotypes
Gm allotypes in plasma samples were analyzed by a qualitative
standard hemagglutination inhibition method [14,15]. In brief,
human blood group O Rh+ erythrocytes were coated with anti-Rh
antibodies of known Gm allotypes. Plasma sample and reagent
monospecific anti-allotype antibody were added. Plasma contain-
ing IgG with a particular Gm allotype inhibited hemagglutination
by the corresponding reagent anti-allotype antibody, whereas
plasma sample that was negative for this allotype did not.
Concerning the infant BEI1, allotype determination was
assessed at 15 months of age to avoid any residual presence of
maternal antibodies [23].
Total IgG3 Purification
Fresh or frozen (at 220uC) plasma samples were tested in
parallel in order to evaluate potential differences in the final result.
Frozen plasma samples were used after centrifugation in order to
eliminate the fibrin aggregates. A quantity of 250 mL of plasma
was sufficient to detect and quantify allotype peptides from
purified total IgG3.
First, a Protein A column (HiTrap Protein A HP, GE
Healthcare, France) was used according to the manufacturer’s
instructions. This column is intended to retain IgG1, IgG2 and
IgG4 leaving IgG3 in the filtrate. Efficient binding of IgG1, IgG2
and IgG4 to the Protein A column necessitates low ionic strength,
a pH value of 7. The flow-through fraction was injected in a
Protein G column (Protein G Sepharose HP SpinTrap, GE
Healthcare, France) which presents high affinity for the Fc
fragment of IgG from a large variety of species including human
IgG3. Antibody binding was performed at neutral pH and elution
was obtained by lowering the pH. The eluted material was
neutralized to preserve the integrity of acid-labile IgG.
Table 2. Cont.
Theoretical proteotypic peptides
CH
domains
Positions in CH
domains [21]
Allotype and other
polymorphic amino
acids [8]
IGHG3
alleles from
IMGT/GENE-
DB [18] G3m alleles
#31 R. WQEGNIFSCSVMHEALHNRFTQK. S CH3 95–120 E98 (G3m6i),
I101 (G3m27, G3m10f),
R115 (G3m26) +
F116 (G3m5, G3m14h)
IGHG3*13 G3m6* G3m5,6,10,11,14,
26,27
#32 R. WQQGNIFSCSVMHEALHNRYTQK. S CH3 95–120 Q98, I101 (G3m27),
R115 (G3m26) +
Y116 (G3m28)
IGHG3*14, *15, *16 G3m21* G3m21,26,27,28
The proteotypic peptides correspond to an enzymatic AspN and trypsin digestion of the constant region of the IG gamma3 chains encoded by the Homo sapiens IGHG3
gene.
aPartial.
bUnusual G3m allele [8,12]. This corresponds to the IGHG3*08 allele. Allotypes G3m10, G3m11 and G3m13 are not expressed owing to the presence of CH3 Asn N44,
instead of the CH3 Ser S44 usually present in the other G3m5* alleles [8].
cThe IGHG3*11 and IGHG3*12 alleles differ by the number of hinge exons, 4 and 3, respectively (IMGT Repertoire, Gene table http://www.imgt.org) [8,18].
dExpression of the allotype G3m15 is dependent, in addition to CH3 Met M39, on the presence of CH3 His H115 and Tyr Y116 [8].
eExpression of the allotype G3m13 is dependent, in addition to CH3 Gln Q98, on the presence of CH3 Ser 44 [8].
fExpression of the allotype G3m10 is dependent, in addition to CH3 Ile I101, on the presence of CH3 Ser 44 [8].
gExpression of the allotype G3m15 is dependent, in addition to CH3 His H115 and Tyr Y116, on the presence of CH3 Met M39 [8].
hExpression of the allotype G3m14 is dependent, in addition to CH3 Arg R115 and Phe F116, on the presence of CH3 Met M84 [8].
iExpression of the allotype G3m6 is dependent, in addition to CH3 Glu E98, on the presence of CH3 Ser S44 [8].
jExpression of the allotype G3m24 is dependent, in addition to CH3 Val V101, on the presence of CH3 Ser S44 [8].
Amino acids in bold are implicated in the discrimination between IGHG3 alleles. ‘‘.’’ : site of enzymatic cut.
Amino acids characteristic of the G3m allotypes and IGHG3 alleles are from reference [8]. They are illustrated in the ‘IMGT G3m allele butterfly’ representation [8]. Amino
acid sequences are available in the IMGT Repertoire (http://www.imgt.org), IMGT/DomainDisplay and IMGT/GENE-DB [18]. Positions in the CH domains are according to
the IMGT unique numbering for C domain [21].
doi:10.1371/journal.pone.0046097.t002
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Table 3. Transitions used in SRM experiments for peptides WQQGNIFSCSVMHEALHNR (#24, G3m5*) and
WQEGNVFSCSVMHEALHNR (#26, G3m24*).
Sequence Precursor 3+ (m/z) Fragment +1 (m/z) Fragment type
WQQGNIFSCSVMHEALHNR 753.0 289.1 y2
WQQGNIFSCSVMHEALHNR 753.0 315.1 b2
WQQGNIFSCSVMHEALHNR 753.0 426.1 y3
WQQGNIFSCSVMHEALHNR 753.0 610.3 y5
WQQGNIFSCSVMHEALHNR 753.0 876.4 y7
WQQGNIFSCSVMHEALHNR 753.0 1007.4 y8
WQQGNIFSCSVMHEALHNR 756.3 299.1 y2
WQQGNIFSCSVMHEALHNR 756.3 315.1 b2
WQQGNIFSCSVMHEALHNR 756.3 436.1 y3
WQQGNIFSCSVMHEALHNR 756.3 620.3 y5
WQQGNIFSCSVMHEALHNR 756.3 886.4 y7
WQQGNIFSCSVMHEALHNR 756.3 1017.5 y8
WQQGNIFSCSVM(ox)HEALHNR 758.3 289.1 y2
WQQGNIFSCSVM(ox)HEALHNR 758.3 315.1 b2
WQQGNIFSCSVM(ox)HEALHNR 758.3 426.1 y3
WQQGNIFSCSVM(ox)HEALHNR 758.3 610.3 y5
WQQGNIFSCSVM(ox)HEALHNR 758.3 876.4 y7
WQQGNIFSCSVM(ox)HEALHNR 758.3 1023.5 y8
WQQGNIFSCSVM(ox)HEALHNR 761.7 299.1 y2
WQQGNIFSCSVM(ox)HEALHNR 761.7 315.1 b2
WQQGNIFSCSVM(ox)HEALHNR 761.7 436.1 y3
WQQGNIFSCSVM(ox)HEALHNR 761.7 620.3 y5
WQQGNIFSCSVM(ox)HEALHNR 761.7 886.4 y7
WQQGNIFSCSVM(ox)HEALHNR 761.7 1033.5 y8
WQEGNVFSCSVMHEALHNR 748.7 289.1 y2
WQEGNVFSCSVMHEALHNR 748.7 315.1 b2
WQEGNVFSCSVMHEALHNR 748.7 426.1 y3
WQEGNVFSCSVMHEALHNR 748.7 610.3 y5
WQEGNVFSCSVMHEALHNR 748.7 876.4 y7
WQEGNVFSCSVMHEALHNR 748.7 1007.4 y8
WQEGNVFSCSVMHEALHNR 752.0 299.1 y2
WQEGNVFSCSVMHEALHNR 752.0 315.1 b2
WQEGNVFSCSVMHEALHNR 752.0 436.1 y3
WQEGNVFSCSVMHEALHNR 752.0 620.3 y5
WQEGNVFSCSVMHEALHNR 752.0 886.4 y7
WQEGNVFSCSVMHEALHNR 752.0 1017.5 y8
WQEGNVFSCSVM(ox)HEALHNR 754.0 289.1 y2
WQEGNVFSCSVM(ox)HEALHNR 754.0 315.1 b2
WQEGNVFSCSVM(ox)HEALHNR 754.0 426.1 y3
WQEGNVFSCSVM(ox)HEALHNR 754.0 610.3 y5
WQEGNVFSCSVM(ox)HEALHNR 754.0 876.4 y7
WQEGNVFSCSVM(ox)HEALHNR 754.0 1023.5 y8
WQEGNVFSCSVM(ox)HEALHNR 757.3 299.1 y2
WQEGNVFSCSVM(ox)HEALHNR 757.3 315.1 b2
WQEGNVFSCSVM(ox)HEALHNR 757.3 436.1 y3
WQEGNVFSCSVM(ox)HEALHNR 757.3 620.3 y5
WQEGNVFSCSVM(ox)HEALHNR 757.3 886.4 y7
WQEGNVFSCSVM(ox)HEALHNR 757.3 1033.5 y8
3+: The precursor ions were in triply-charged form; m/z: mass to charge ratio; ox: oxidized methionine (M), accepted nomenclature for fragment ions as proposed by
Roepstorff and Fohlman [25]; bolded are the heavy arginine.
doi:10.1371/journal.pone.0046097.t003
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Validation of IgG3 Purification
Validation of IgG3 purification was tested on several samples.
All filtrate and elution fractions from Protein A and Protein G
affinity chromatography were either migrated on a 12% Sodium
Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE)
or assayed in an Enzyme-Linked ImmunoSorbent Assay (ELISA)
in order to measure the quantities of IgG3 all along the
purification process. SDS-PAGE was performed on the EUA1
fractions and ELISA on BEC3 and BEC4 fractions.
Briefly, for the SDS-PAGE, 15 mL of a 2X b-mercaptoethanol/
Laemmli buffer were added to 15 mL of filtrate or elution
fractions. After boiling at 100uC for 5 minutes, samples were
migrated on a 12% SDS-PAGE. Gels were colored with colloidal
Coomassie Blue. For the ELISA, a total of 100 mL of a Phosphate
Buffered Saline (PBS) solution containing 0.1 mg of a mouse
monoclonal anti-human IgG3 (clone ZG4, gift from P. Aucou-
turier) were coated in a 96-well plate (Thermo Fisher Scientific,
San Jose´, CA) overnight at 4uC. Wells were blocked with 150 mL
of PBS added with 4% Bovine Serum Albumin (BSA). After 4
washes, each fraction diluted 1/100 000 was incubated 1 hour at
37uC. Controls were constituted with a pool of European sera. A
human monoclonal purified IgG3 (Binding Site, UK) was used as
standard. A horseradish peroxidase (HRP)-conjugate goat anti-
human IgG (Sigma Aldrich, France) was incubated for 1 hour at
room temperature. Reading was done at 420 nm 10 minutes after
addition of 3,39,5,59-tetramethylbenzidine (Microwell Peroxidase
substrate, KPL, USA).
Reduction, Alkylation and Enzymatic Digestion
Dithiothreitol (DTT, 20 mM) was added to 37 mL of purified
samples for 30 minutes at 56uC in order to reduce disulfide bonds.
Except for SRM experiments, chloroacetamide (final concentra-
tion 25 mM) was added for 30 minutes at room temperature for
protecting thiol groups. AspN (Roche Diagnostics, France, 10 ng/
mL) was added before incubation for 3 hours at 37uC or overnight
at 30uC. The same incubation conditions were then applied to
trypsine (Promega, France, 10 ng/mL). The enzymatic digestion
was stopped with trifluoroacetic acid (TFA, Pierce, France, 0.5%
final).
Purified samples from either fresh or frozen plasma samples
show no difference in the final results. The treatment of IgG3
purified samples with GluC or with papaı¨ne before AspN and
trypsin digestion was tested on several samples but did not bring
improvements in the final results.
Mass Spectrometry (MS) Analysis
Nano-liquid chromatography (nLC) MALDI time-of-flight
(TOF) MS and tandem mass spectrometry (MS/
MS). Peptides were concentrated and separated by nano
High-Performance Liquid Chromatography (nHPLC) using an
UltimateH 3000 (Dionex, Netherlands). Briefly, 10 ml of elution
fraction were injected and trapped using solvent A (TFA 0.1%,
acetonitrile (ACN, Carlo-Erba, France) 2%) at a 30 mL/minute
loading flow rate for 3 min in a C18 trap column (C18 PepMap,
5 mm, 100 A˚, 300 mm i.d., 5 mm length) and separated in the
analytical column (C18 PepMap, 3 mm, 100 A˚, 75 mm i.d., 15 cm
length) with a discontinuous gradient from 7% solvent B (ACN
80%, solvent A 20%) to 20% in 7 min and from 20% to 60% in
58 min at 300 nL/min. A Probot (Dionex, France) fraction
collector was used to spot 192 collected fractions on a MALDI
target (ion source). Spotted fractions were mixed 1:9 (v/v) with
2 mg/mL of alpha-cyano-4-hydroxycinnamic acid (HCCA, Laser
Biolabs) in ACN 70% TFA 0.1% containing 3 fmoles/spot of a
standard peptide (Glu fibrinopeptide) and analyzed by time-of-
flight (TOF) (mass analyzer), using a 4800 MALDI TOF/TOFTM
analyzer (Applied Biosystems, France).
Spectra acquisition and processing were performed using the
4000 Series ExplorerTM software (Applied Biosystems, France)
version 3.5 in positive reflectron mode at fixed Laser fluency with
low mass gate and delayed extraction. External plate calibration
was performed using 4 calibration points spotted throughout the
Figure 1. Protein-A and Protein-G purification fractions from the EUA1 plasma sample on an acrylamid gel. A. 12% SDS-PAGE in non-
reducing conditions: lines AF1 to AF3: consecutive filtrate fractions of a Protein A column containing plasma proteins including IgG3; line AE: Elution
fraction of a Protein A column containing IgG1, IgG2, IgG4; lines GE1 and GE2: consecutive elution fractions of a Protein G column containing IgG3. B.
12% SDS-PAGE in reducing conditions: lines GE1 and GE2: consecutive elution fractions of a Protein G column containing IgG3.
doi:10.1371/journal.pone.0046097.g001
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plate, and internal calibration using Glu-fibrinopeptide yielded
under 20 ppm accuracy. For each MALDI spot, 500 spectra (10
sets of 50 averaged Laser shots) were acquired and summed in the
700 to 4000 m/z range. The data above signal-to-noise (s/n) ratio
of 20 were filtered before deisotoping. In each MALDI spot, the 8
most abundant peaks (minimum s/n 20) were selected for
fragmentation by collision-induced dissociation (CID) starting
with the least abundant. Neighboring precursors within resolution
of 200 were excluded. One thousand MS/MS spectra per
precursor were summed by increments of 50.
Processing included baseline subtraction and Stavitsky Golay
smoothing with 3 points across peak and a polynomial order of 4.
Peak lists reflect monoisotopic values from isotope clusters with an
s/n ratio of minimum 22. Generated MS/MS peak lists were
subsequently submitted to an in-house Mascot (Matrix science)
version 2.2 search engine [24] to identify peptides (detailed in the
‘‘Database searching’’ paragraph).
nLC Linear Trap Quadrupole (LTQ) ESI Orbitrap MS and
MS/MS. A nanoHPLC system UltimateH 3000 Rapid Separa-
tion Liquid Chromatographic (RSLC) (Dionex, Netherlands) was
coupled to an Orbitrap Velos (Thermo Fisher Scientific, San Jose´,
CA), hybrid mass spectrometer that combines a LTQ ion trap in
ESI mode and an Orbitrap mass analyzer technology. Briefly,
peptides were desalted on a C18 reverse phase precolumn (C18
PepMap, 3 mm, 100 A˚, 75 mm i.d., 2 cm length) using a loading
buffer containing H2O/ACN/TFA 98:2:0.1 (v/v) at 5 mL/min.
Peptides were then separated on a C18 reverse phase analytical
column (C18 PepMap, 2 mm, 100 A˚, 75 mm i.d., 15 cm length)
with a 45 min gradient from 100% A (H2O/ACN/formic acid
95:5:0.1 (v/v/v)) to 40% B (H2O/ACN/formic acid 20:80:0.085
(v/v/v)).
Data dependent acquisition with the Orbitrap Velos was done
throughout the elution process: 1 full scan MS was followed by up
to 10 LTQ MS/MS CID spectra on the most abundant
precursors detected in the MS scan with a dynamic exclusion of
24 seconds for previously fragmented precursors. Mass spectrom-
eter settings were: full MS (Automatic Gain Control (AGC): 1E6,
resolution: 3E4, m/z range 400–2000, maximum ion injection
time: 1000 ms); MS/MS (AGC: 1E4, maximum injection time:
200 ms, minimum signal threshold: 2000, isolation width: 2 Da).
Figure 2. ESI MS/MS fragmentation profiles from three main proteotypic allelic peptides. Y axis represents the logarithm of the relative
abundance +1, x axis represents the mass to charge ratio (m/z). A. Spectra from the sample (BEC1), fragmentation of peptide (#24, G3m5*)
(IGHG3*01,*04 to*07, *09 to*12, CH3 95–116). The database search identifies the sequence 332–350 for IMGT reference AJ390260|IGHG3*15. This
sequence is found in 9 IGHG3 alleles of G3m5* and is identical to peptide (#25, G3m21*) found in 3 IGHG3 alleles (of which IGHG3*15) of G3m21* (as
detailed in Table 2 and discussed in 2.1). In BEC1, the parallel identification of the (#19, G3m5) peptide confirmed that indeed the fragmented
peptide is (#24, G3m5*) (1+)y fragment ion series for m/z 1129.02 with 2 charges and free cysteine; accepted nomenclature for fragment ions as
proposed by Roepstorff and Fohlman [25]. B. Spectra from the sample (BEC2), fragmentation of peptide (#26, G3m24*) (IGHG3*03, CH3 95–116),
sequence 347–365 for IMGT reference X16110|IGHG3*03. In this case, the peptide (#26, G3m24*) is highly discriminatory as it corresponds not only
to a single allotype (G3m24*) but also to a single IGHG3 allele (IGHG3*03), (1+)y fragment ion series for m/z 1122.50 with 2 charges and free cysteine.
C. Spectra from the sample (BEM3), fragmentation of peptide (#27, G3m26*) (IGHG3*13, CH3 95–116), sequence 347–365 for IMGT reference
AJ390244|IGHG3*13. As in (B), the peptide (#27, G3m26*) is highly discriminatory as it corresponds to a single allotype (G3m6*) and to a single IGHG3
allele (IGHG3*13), (1 or 2+)y or (1+)b fragment ion series for m/z 753.02 with 3 charges and free cysteine.
doi:10.1371/journal.pone.0046097.g002
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The fragmentation was permitted for precursors with a charge
state of 2, 3 or 4.
The Progenesis LC-MS software (Version 3.0; Nonlinear
Dynamics Ltd) for label-free semi-quantitative data analysis was
used to quantify the variation of discriminatory peptides on the
basis of retention time, m/z and peak intensity (peak area) on
samples. Progenesis software processed the raw data files in two
steps: alignment followed by normalization. The data file that
yielded most features (ratio 1:1) was used as reference to align
retention time in all other measurements. Correction for
experimental variations was done by calculating the robust
distribution of all ratios (log (ratio)). The peaks (the features)
were converted into intensity lists by using the raw data files.
The data were filtered using the following criteria: features with
masses between 300 and 1700 Da, retention time 8–25 minutes
and charge state 2 to 4. A matrix of all samples was generated,
consisting of all masses with corresponding peak intensities of
every sample. A resulting.mgf file was exported from Progenesis
and imported in Mascot software, interrogation was performed
on a home-made database (detailed in the ‘‘Database searching’’
paragraph). A resulting XML file was then imported in
Progenesis to assign peptides to features. The results of
normalized peptide abundances were analyzed using Excel
software.
nLC Selected Reaction Monitoring (SRM) on Triple
quadrupole mass spectrometry. An UltimateH 3000 RSLC
(Dionex, Netherlands) coupled to a TSQ VantageTM mass
spectrometer (Thermo Fisher Scientific, San Jose´, CA) in ESI
mode. Briefly, peptides were loaded and washed on a C18
reverse phase precolumn (C18 PepMap, 3 mm, 100 A˚, 75 mm
i.d., 2 cm length) using a loading buffer containing H2O/CAN/
TFA 98:2:0.05 (v/v/v) at 6 mL/min. Peptides were then
separated on a C18 reverse phase analytical column (C18
PepMap, 2 mm, 100 A˚, 75 mm i.d., 15 cm length) with a 60 min
gradient from 99% A (H2O/ACN/formic acid 98:2:0.1 (v/v/v))
to 50% B (H2O/ACN/formic acid 10:90:0.1 (v/v/v)) at
300 nL/min. All the data were acquired in triplicate and blank
runs were interposed until necessary to avoid peptide carry-over
effects. SRM acquisitions were performed in scheduled mode.
The SRM transitions (precursor/product pairs) were recorded at
the retention time +/24 min as measured during the optimi-
zation step. In the most complex part of the chromatogram,
where transitions overlap the most, the dwell time associated to
the SRM method is less than 2s. The first and third quadrupole
were set to 0.7 Da peak width and the transitions were chosen
as detailed in Table 3 [25]. For all the transitions related to the
WQQGNIFSCSVMHEALHNR (#24 G3m5*) and
WQEGNVFSCSVMHEALHNR (#26 G3m24*) peptides dwell
time of 100 ms was used. The sensitivity threshold tested with
AQUATM peptides (Thermo Fisher, Germany) was 10 fmol of
injected peptide. AQUATM peptides are synthetic peptides,
chemically identical with the same structure but isotopically
modified using incorporating heavy and stable isotopes (13C or
15N) spiked in the biological sample in order to serve as
internal standards for chromatographic normalization (retention
time and peak area).SRM data processing and absolute
quantitation using AQUATM peptides were performed by
Pinpoint version 1.2 (Thermo Fisher, Germany).
Database searching. MS/MS spectra originating from mass
spectrometers were submitted to Mascot. The database search was
a home-made concatenation of IMGTH IGHG allele database
[18,20] (IMGT Repertoire. Sections: Protein displays, Alignments
of alleles, http://www.imgt.org), with the SwissProt fasta database
release 2011_01, 529 942 sequences, 189 364 547 residues. The
precursor mass tolerance was set to 20 or 3 ppm for MALDI MS
and ESI LTQ MS respectively, and the fragment mass tolerance
to 0.35 and 0.45 Da for MALDI MS/MS and ESI LTQ MS/MS,
respectively. Two miscleavages and the partial oxidation of
methionines were permitted. The search was not species-restricted.
Selected enzymes were AspN and Trypsin. A filter was applied to
the search in order to keep the probability of false positive peptide
identification below 5%. A minimum Mascot score value of 25 was
set for peptide selection.
Results
IgG3 Purification from Plasma Samples
The SDS-PAGE was performed on EUA1. On the non-
reducing SDS-PAGE (Figure 1A), the filtrate fractions of the
Protein A column (AF) were constituted by many plasma proteins
including the IgG3 with a band at 160 kDa approximately,
whereas the elution fraction (AE) contained a majority of the other
subclasses (IgG1, IgG2 and IgG4). The elution fraction from the
Protein G column (GE) contained enriched IgG3 (22% of plasma
IgG3) but also unexpected plasma proteins. On the reducing SDS-
PAGE (Figure 1B), dissociated IgG3 heavy and light chains
migrated at 65 kDa and 20 kDa, respectively. The measurement
of IgG subclass levels by ELISA on BEC3 and BEC4 revealed an
abnormal presence of IgG3 in the AE fraction (24.4% of plasma
IgG3 were found in this fraction).
In conclusion, the use of Protein A and G columns allowed a
final enrichment of IgG3 in GE (27% and 81%, respectively),
although with a loss of IgG3 and without being exclusive of the
other IgG subclasses. As the list of discriminatory peptides defined
in Table 1 is specifically representative of IGHG3, the mass
spectrometric analysis should not be hampered by the presence of
contaminating heavy chains from IgG1, 2 and 4.
Detection of Distinct Proteotypic G3m Allotype Peptides
by Mass Spectrometry
Experiments were first done on plasma samples from three
Beninese individuals known to harbor distinct G3m alleles: BEC1
homozygous for G3m5*, BEC2 heterozygous for G3m5*/
G3m24* and BEM3 heterozygous G3m5*/G3m6*, and then on
the other seven samples Altogether eight discriminatory peptides
were detected. They included three peptides for G3m5* (#15,
#19,#24), four peptides for G3m24* (#11,#21,#26,#30), and
one peptide for G3m6* (#27). The (#24, G3m5*) and (#26,
G3m24*) peptides were found as expected, based on the
corresponding serological data of the samples, and on the results
of the MS/MS, but with MALDI having missing peaks compared
to Orbitrap. At this proof of concept stage, these experimental
Figure 3. Relative abundance of a volume/volume mixture from BEC1 (G3m5*) and BEC2 (G3m5*/G3m24*) plasma samples. The
relative abundance was calculated by the Progenesis LC-MS software for label-free semi-quantitative data analysis (detailed in 2.7); +2: dicharged
peptides; the light grey bars represent the measure of the WQEGNVFSCVMHEALHNR (#26, G3m24*) peptide (only brought by BEC2), the dark grey
bars taken all together represent the measure of the WQQGNIFSCVMHEALHNR (#24, G3m5*) peptide (brought by both BEC1 and BEC2). The dark
grey bars were divided into a hatched part (for the deduced signal attributable to BEC2, calculated from the 0:1 ratio) and a non-hatched part (for the
deduced signal attributable to BEC1).
doi:10.1371/journal.pone.0046097.g003
MS/MS Detection of G3m, IGHG3 Alleles and IgG3
PLOS ONE | www.plosone.org 11 September 2012 | Volume 7 | Issue 9 | e46097
MS/MS Detection of G3m, IGHG3 Alleles and IgG3
PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e46097
differences that do not interfere with the final results will be
explored further but are not discussed here. Interestingly, the
presence of unexpected peptides corresponding to three G3m
alleles in a single sample may be explained by the cross-
contamination of the samples.
The fragmentation profiles of the three discriminatory peptides
WQQGNIFSCSVMHEALHNR (#24, G3m5*), WQEGNVFS
CSVMHEALHNR (#26, G3m24*) and WQEGNIFSCSVM-
HEALHNR (#27, G3m6*) detected and identified by the
Orbitrap are shown in Figure 2. The peptides WQQGNIF
SCSVMHEALHNR (#24, G3m5*) and WQEGNVFSCSVM-
HEALHNR (#26, G3m24*) for which AQUA peptides were
available were also detected, identified and quantified by the SRM
method (Table 3).
These results demonstrate that MS allows identifying the
proteotypic peptides that characterize G3m and IGHG3 alleles
and therefore represents a choice method for the analysis of the
IGHG3 amino acid polymorphisms.
Application of the Mass Spectrometry Approach to a
Mixture of Plasma Samples
In order to evaluate the sensitivity and specificity of the
methodology, volume/volume ratios of 1:0, 16:1, 8:1, 4:1, 2:1, 1:1,
1:2, 1:4, 1:8, 1:16, 0:1 were prepared with IgG3 purified fractions
from BEC1 (homozygous for G3m5*) and BEC2 (heterozygous for
G3m5*/G3m24*) samples before their reduction, alkylation and
enzymatic digestion (Figure 3). As a reminder, both samples
shared the WQQGNIFSCSVMHEALHNR peptide (#24,
G3m5*) and BEC2 presented the additional
WQEGNVFSCSVMHEALHNR peptide (#26, G3m24*). This
experiment illustrates the artificial mixture of mother and child
IgG3 in an infant plasma sample, in the case of one of them being
heterozygous for 2 distinct G3m alleles and the other homozygous
for one of these alleles (Figure 3). The respective signal intensities
were measured by the Progenesis software.
The most diluted peptides in the 1:16 and 16:1 ratios were
successfully detected, demonstrating the high sensitivity and
specificity of the method. Furthermore the signal intensities were
adequately related to the real ratios of the sample mixtures.
The 1:0 and 0:1 ratios presented different relative abundances
that were related to their absolute quantification made by SRM.
Indeed, in the BEC1 sample that is homozygous G3m5*, the
concentration of WQQGNIFSCSVMHEALHNR (#24, G3m5*)
was 262.2+/213.4 fmol/mL whereas, as expected,
WQEGNVFSCSVMHEALHNR (#26, G3m24*) was absent. In
the BEC2 sample that is heterozygous G3m5*/G3m24*, the
concentrations of WQQGNIFSCSVMHEALHNR (#24,
G3m5*) and WQEGNVFSCSVMHEALHNR (#26, G3m24*)
were 56.0+/24.9 fmol/mL and 990.3+/220.7 fmol/mL, respec-
tively. The 0:1 ratio represented the relative quantities of
proteotypic peptides brought by each of the 2 polymorphic
gamma3 chains of BEC2. Considering that the ratio between these
2 peptides was constant and applicable to each volume mixture, it
was possible to deduce the quantity of WQQGNIFSCSVM-
HEALHNR (#24, G3m5*) attributable to BEC1 and BEC2,
respectively (Figure 3).
Application of the Mass Spectrometry Approach to
Paired Mother and Child Plasma Samples
MS analysis was performed on total IgG3 purified from plasma
samples of one Beninese mother (BEM1) and her baby (BEI1: cord
blood, 3, 6 and 9 months) (Figure 4). As the mother BEM1 was
serologically identified as G3m5*/G3m24* heterozygous, a
combination of the peptides WQQGNIFSCSVMHEALHNR
(#24, G3m5*) and WQEGNVFSCSVMHEALHNR (#26,
G3m24*) was expected. The child BEI1 being homozygous for
G3m5*, the sole presence of the WQQGNIFSCSVMHEALHNR
peptide (#24, G3m5*) was expected.
The graph in Figure 4 illustrates the decrease in the
WQQGNIFSCSVMHEALHNR peptide (#24, G3m5*) between
birth (CO sample) or three months of age (M3 sample) and six
months of age (M6 sample) (Figure 4A). This is concomitant to the
loss of maternal-transmitted IgG3 which partially comprise this
peptide. At nine months of age (M9 sample), only the
WQQGNIFSCSVMHEALHNR peptide (#24, G3m5*) corre-
sponding to IgG3 neo-synthesized by the infant is visualized.
The WQEGNVFSCSVMHEALHNR peptide (#26, G3m24*)
was expected in the mother’s sample (CI) as well as in the samples
corresponding to the first months of life of her child (CO, M3,
M6), but it was not visualized in the Orbitrap. The detection
threshold of these peptides seems to be too low in the sample.
Therefore, the optimized SRM strategy was used to monitor the
WQEGNVFSCSVMHEALHNR (#26, G3m24*) and
WQQGNIFSCSVMHEALHNR (#24, G3m5*) peptides with
their corresponding AQUA peptides. The WQQGNIFSCSVM-
HEALHNR (#24, G3m5*) peptide was found and quantified in
agreement with the Orbitrap data (Figure 4B) but the detection of
peptide WQEGNVFSCSVMHEALHNR (#26, G3m24*) was
not possible in this particular case of mother-child pair samples.
Two hypotheses may be proposed whereby i) BEM1 could be
homozygous for the G3m5* allele inversely to the results provided
by the hemagglutination inhibition method or ii) the
WQEGNVFSCSVMHEALHNR (#26, G3m24*) signal was
undetected because it was under the signal/noise ratio.
In conclusion, both quantitative methods, either relative or
absolute, provided satisfactory detection of the expected peptides
from the two alleles whether in the artificial mixture or in the
mother/neonate sera. Protein carbamidomethylation of cysteins
was skipped in SRM experiments to avoid ‘‘multiple signals’’ of the
peptide due to incomplete reaction.
Discussion
MS methodology for the detection and quantification of the
G3m and IGHG3 alleles is described. At each step, from plasma
purification up to peptide sequence analysis, the most adequate
amongst different tested protocols were chosen. The IgG3
purification step is a crucial point. Affinity chromatography using
successively Protein A and Protein G columns was chosen in the
present study. An alternative choice would be to process plasma
samples on fast protein size-exclusion liquid chromatography in
order to optimize the quantity of recovered material and also to
standardize the experiment thanks to an automated system. The
purification yield of the protein A column was not satisfying in the
Figure 4. Relative abundance of peptide WQQGNIFSCSVMHEALHNR (#24, G3m5*) in a mother and her newborn plasma samples.
CI =mother circulating plasma, CO=plasma from cord blood, M= Infant plasma at 3, 6 and 9 months; result based on 3 technical replicates. A. the
peptide signals were measured by LTQ Orbitrap and the relative abundance was calculated by the Progenesis LC-MS software. B. the peptide signals
were measured by SRM.
doi:10.1371/journal.pone.0046097.g004
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present study and an improvement of the IgG purification process
could consist in the sole use of the protein G column.
The peptide cartography obtained with the MALDI was
incomplete probably because of a lack of ionization efficiency.
The electrospray ionization analysis led to the detection of
multicharged peptides and seemed therefore adapted to this
problematic. The highly resolutive Orbitrap analyzer allowed an
accurate detection of the proteotypic peptides. This detection was
satisfying in the mixture of plasma samples with distinct G3m
alleles (Figure 3): the concomitant increases and decreases of two
proteotypic peptides contained in preparations which were mixed
at sequential ratios allowed validating the relative quantification in
a label free approach. In spite of some improvements that are yet
to be brought, this study represents the first demonstration of the
technical feasibility of detecting peptides representing distinct
G3m and IGHG3 alleles.
The detection of peptide WQQGNIFSCSVMHEALHNR
(#24, G3m5*) in the samples of the mother-child pair (BEM1
and BEI1) presents the same profile in the Orbitrap and the triple
quadrupole in SRM mode (Figure 4). Peptide
WQEGNVFSCSVMHEALHNR (#26, G3m24*) was detected
and identified in several samples (e.g., BEC2, BEC3, BEC4,
BEM2), but it was not, although expected from serological data, in
the mother and child samples (BEM1, BEC1). Two explanations
may be proposed to account for the absence of this peptide: 1)
BEM1 brought effectively only the G3m5* allele or 2) it could not
be detected on account of insufficient quantity. The first
hypothesis considers the sensitivity of the standard hemagglutina-
tion inhibition method. As a reminder, this method is qualitative.
Its advantage is to detect Gm allotype epitopes but at the same
time this makes the results dependent on the specificity of the
reagent anti-allotype antibodies and on visual interpretation. As
regards the second hypothesis, the quantities of the distinct G3m
allele peptides contained in a heterozygous individual sample
could be impacted by the purification process. To validate this
possibility a relative or absolute quantification of peptides could be
processed by mass spectrometry on each purification fraction as
well as directly on plasma samples. Another explanation could be
that an individual heterozygous for G3m alleles could express
differently each of them, as shown for the G1m alleles [26], despite
the fact that Gm allotypes are encoded by codominant genes [8].
This possibility was reinforced by the results of the absolute
quantification of the 2 peptides detected in the BEC2 sample,
WQQGNIFSCSVMHEALHNR (#24, G3m5*) and
WQEGNVFSCSVMHEALHNR (#26, G3m24*), for which the
concentrations were 56.0 and 990.3 fmol/mL, respectively, with
comparable ionization efficiency of the SRM analysis. In the
mother-child samples (BEM1, BEI1), WQEGNVFSCSVM-
HEALHNR (#26, G3m24*) may have been present but in
quantities below the signal/background threshold. The triple
quadrupole in SRM mode would be the adequate equipment in
the cases where the measurement of an absolute quantity of
peptides would be necessary.
The G3m and IGHG3 allele identification based on mass
spectrometry may be applied at distinguishing maternal from
neonatal antibodies in plasma samples from infants. In their first
months of life, newborns are protected by maternal antibodies
transferred through the placenta. After a few months, the
concentration of maternal antibodies decreases in the infant’s
plasma, giving way to neo-synthesized neonatal antibodies.
Quantification of polymorphic peptides for the detection of
G3m and IGHG3 alleles may allow following the IgG3 expression
in neonates provided that the IGHG3 polymorphisms from the
mother and her child are distinct. Restrictions encountered in the
case of identical IGHG3 alleles in both mother and child can be
overcome by the recourse to the IGHG1 polymorphism alleles
and, although less informative, to the IGHG2 and IGHG4 alleles
[8], thus reinforcing the capacity to distinguish maternal from
infant IGHG alleles. In a recent publication, Goetze and co-
workers [26], using similar MS tools, have circled peptides of close
homology to those investigated here, from IGHG1 and IGHG2,
however this work has mostly focused on glycosylation but not on
quantification. The detection and quantification of the neonate’s
own antibody response might be essential in some clinical cases in
terms of indirect diagnosis. In the case of infections of the
newborns [27–30], it may be foreseen that the specific IgG
produced in neonates be followed, providing by their decrease,
information on the response to therapeutic treatment.
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